X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01.
Lead Product(s): CG01
Therapeutic Area: Neurology Product Name: CG01
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: CombiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
Cobra Biologics has successfully produced and supplied further two DNA plasmids for the production of CombiGene AB’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy.
Lead Product(s): DNA plasmids
Therapeutic Area: Neurology Product Name: CG01
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CombiGene AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 13, 2020
Details:
Cobra will provide Astrazenrca with GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.
Lead Product(s): AZD1222
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2020
Details:
Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy.
Lead Product(s): CG01
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
The funding will leverage phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic.
Lead Product(s): DNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Karolinska Institutet
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Funding March 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
